Invest now
Pfizer share price
Balanced risk
- ₹4,598.30(0.53%)July 21, 2026 15:27:58 PM IST
- NSE
- BSE
- Vol : 17.58 K (NSE + BSE)Last 20 day avg : 33.85 K
Pfizer is trading 0.53% upper at Rs 4,598.30 as compared to its last closing price. Pfizer has been trading in the price range of 4,619.85 & 4,541.40. Pfizer has given -8.22% in this year & -3.34% in the last 5 days. Pfizer has TTM P/E ratio 29.89 as compared to the sector P/E of 25.57.There are 5 analysts who have initiated coverage on Pfizer. There are 3 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 199.82 Crores in its last quarter.Listed peers of Pfizer include Aurobindo Pharma (0.66%), Neuland Laboratories (-0.27%), Unichem Laboratories (-1.28%).The Mutual Fund holding in Pfizer was at 12.68% in 30 Jun 2026. The MF holding has increased from the last quarter. The FII holding in Pfizer was at 1.65% in 30 Jun 2026. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 21 Jul 2026, 04:35 PM IST
- BetaLow volatility0.63Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.02The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldHigher than industry1.64Annual dividends as a percentage of the stock price.
- PEG RatioIndicates overvaluation5.77The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Pfizer News
Pfizer Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Aurobindo Pharma | 1,570.90 | 0.66 | 90,555.23 | 25.34 | 2.37 | - | - |
| Neuland Laboratories | 18,890.00 | -0.27 | 24,303.27 | 65.39 | 12.83 | - | - |
| Unichem Laboratories | 587.40 | -1.28 | 4,135.64 | 55.73 | 1.57 | - | - |
| Jagsonpal Pharmaceuticals | 222.20 | -0.43 | 1,457.69 | 34.70 | 5.5 | - | - |
| Themis Medicare | 112.60 | -0.31 | 1,037.49 | 646.69 | 2.6 | - | - |
Mutual Fund Ownership
View allPfizer Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-05-12 | Audited Results & Final Dividend |
| 2026-02-09 | Quarterly Results |
| 2025-11-12 | Quarterly Results |
| 2025-08-13 | Quarterly Results |
| 2025-05-19 | Audited Results & Special Dividend |
About the company Pfizer
- IndustryMajor Drugs
- ISININE182A01018
- BSE Code500680
- NSE CodePFIZER
Pfizer Limited (Pfizer) is an India-based multinational pharmaceutical company focusing on therapy in four business categories, namely, Vaccines, Hospitals, Internal Medicine, and Inflammation and Immunology. Pfizer’s Vaccines Division focuses on Prevenar 13, a Pneumococcal Conjugate Vaccine approved for administering to individuals of all ages against pneumococcal disease, an infection caused by streptococcus pneumoniae bacteria. Internal Medicine portfolio includes approximately 17 specialties and seven therapy areas, including respiratory, multivitamin and multimineral, gastrointestinal, pain, neuroscience, cardiovascular and women’s healthcare. Pfizer Hospital Business Unit focuses on providing advanced anti-infectives to institutions such as hospitals and nursing homes. Inflammation and Immunology focuses on discovering and developing novel therapeutics for chronic autoimmune diseases. Its brands include Prevenar13, CorexDX, Dolonex, Enbrel, Becosules and Folvite, among others.
Pfizer Share Price FAQs
Pfizer is trading at 4598.30 as on Tue Jul 21 2026 09:57:58. This is 0.53% upper as compared to its previous closing price of 4573.85.
The market capitalization of Pfizer is 20990.32 Cr as on Tue Jul 21 2026 09:57:58.
The average broker rating on Pfizer is Strong Buy. The breakup of analyst rating is given below -
- 3 analysts have given a strong buy rating
- 1 analysts have given a buy rating
- 1 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Pfizer is 5878.55 whereas the 52 wk low is 4361.00
Pfizer can be analyzed on the following key metrics -
- TTM P/E: 29.89
- Sector P/E: 25.57
- Dividend Yield: 1.64%
- D/E ratio: 0.02
Pfizer reported a net profit of 722.43 Cr in 2026.
The Mutual Fund Shareholding was 12.68% at the end of 30 Jun 2026.
Quick Links
EQUITY QUICK LINKS
Pfizer QUICK LINKS
FROM MARKETS
RELATED LINKS
Quarterly Results
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.